Cargando…

Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma

BACKGROUND: Fibulin-3 is a new potential biomarker for malignant mesothelioma (MM). This study evaluated the potential applicability of fibulin-3 plasma levels as a biomarker of response to treatment and its prognostic value for progressive disease within 18 months. The potential applicability of fi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kovac, Viljem, Dodic-Fikfak, Metoda, Arneric, Niko, Dolzan, Vita, Franko, Alenka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Versita, Warsaw 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4577225/ https://www.ncbi.nlm.nih.gov/pubmed/26401134 http://dx.doi.org/10.1515/raon-2015-0019

Ejemplares similares

Soluble Mesothelin-Related Peptides Levels in Patients with Malignant Mesothelioma
por: Franko, Alenka, et al.
Publicado: (2012)

Serum Survivin Levels and Outcome of Chemotherapy in Patients with Malignant Mesothelioma
por: Goričar, Katja, et al.
Publicado: (2015)

Serum Calretinin as a Biomarker in Malignant Mesothelioma
por: Zupanc, Cita, et al.
Publicado: (2021)

The Influence of Genetic Variability on the Risk of Developing Malignant Mesothelioma
por: Franko, Alenka, et al.
Publicado: (2018)

Inducible Nitric Oxide Synthase Genetic Polymorphism and Risk of Asbestosis
por: Franko, Alenka, et al.
Publicado: (2011)

Manganese and Extracellular Superoxide Dismutase Polymorphisms and Risk for Asbestosis
por: Franko, Alenka, et al.
Publicado: (2009)

NLRP3 and CARD8 polymorphisms influence risk for asbestos-related diseases
por: Franko, Alenka, et al.
Publicado: (2020)

Evaluation of Soluble Mesothelin-related Peptides and MSLN Genetic Variability in Asbestos-related Diseases
por: Goricar, Katja, et al.
Publicado: (2020)

The Role of Polymorphisms in Glutathione-related Genes in Asbestos-related Diseases
por: Franko, Alenka, et al.
Publicado: (2021)

Genetic Polymorphisms in Aquaporin 1 as Risk Factors for Malignant Mesothelioma and Biomarkers of Response to Cisplatin Treatment
por: Senk, Barbara, et al.
Publicado: (2019)

The Influence of Genetic Variability of DNA Repair Mechanisms on the Risk of Malignant Mesothelioma
por: Levpuscek, Kristina, et al.
Publicado: (2019)

The Influence of Genetic Variability in IL1B and MIR146A on the Risk of Pleural Plaques and Malignant Mesothelioma
por: Piber, Petra, et al.
Publicado: (2020)

The Influence of Gene-Gene and Gene-Environment Interactions on the Risk of Asbestosis
por: Franko, A., et al.
Publicado: (2013)

Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma
por: Štrbac, Danijela, et al.
Publicado: (2017)

Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma
por: Goričar, Katja, et al.
Publicado: (2017)

Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma
por: Štrbac, Danijela, et al.
Publicado: (2019)

Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma
por: Goricar, Katja, et al.
Publicado: (2014)

Sickness Presence among Disabled Workers at the University Medical Centre Ljubljana
por: ŠKERJANC, Alenka, et al.
Publicado: (2014)

Sickness Presence among Health Care Professionals: A Cross Sectional Study of Health Care Professionals in Slovenia
por: Skerjanc, Alenka, et al.
Publicado: (2020)

Matrix Metalloproteinases Polymorphisms as Baseline Risk Predictors in Malignant Pleural Mesothelioma
por: Strbac, Danijela, et al.
Publicado: (2018)

Extracellular Vesicle Enriched miR-625-3p Is Associated with Survival of Malignant Mesothelioma Patients
por: Goričar, Katja, et al.
Publicado: (2021)

The association of genetic factors with serum calretinin levels in asbestos-related diseases
por: Zupanc, Cita, et al.
Publicado: (2023)

The Influence of Workers’ Health Status on Employers’ Decision-Making During Personnel Restructuring in a Typical Public Limited Enterprise in Slovenia
por: MARGAN, Andrea, et al.
Publicado: (2015)

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis
por: Kirschner, Michaela B, et al.
Publicado: (2015)

Hospital Staff’s Risk of Developing Musculoskeletal Disorders, Especially Low Back Pain
por: Hafner, Nataša Dernovšček, et al.
Publicado: (2018)

Occupational Exposure to Silica Dust in Slovenia is Grossly Underestimated
por: Margan, Andrea, et al.
Publicado: (2023)

Matrix Metalloproteinases as Biomarkers and Treatment Targets in Mesothelioma: A Systematic Review
por: Štrbac, Danijela, et al.
Publicado: (2021)

Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis
por: Ren, Ran, et al.
Publicado: (2016)

Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients
por: Kovac, Viljem, et al.
Publicado: (2012)

Novel and Future Treatment Options in Mesothelioma: A Systematic Review
por: Štrbac, Danijela, et al.
Publicado: (2022)

Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis
por: Pei, Dongxu, et al.
Publicado: (2017)

Homologous Recombination Repair Polymorphisms and the Risk for Osteosarcoma
por: Goričar, Katja, et al.
Publicado: (2015)

Correction: Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis
por: Pei, Dongxu, et al.
Publicado: (2018)

Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a comparative study of pharmacokinetic models and correlation with mRECIST criteria
por: Vivoda Tomšič, Martina, et al.
Publicado: (2019)

Dynamic contrast-enhanced MRI in malignant pleural mesothelioma: prediction of outcome based on DCE-MRI measurements in patients undergoing cytotoxic chemotherapy
por: Vivoda Tomšič, Martina, et al.
Publicado: (2022)

Overexpression of fibulin-3 in tumor tissue predicts poor survival of malignant mesothelioma patients from hand-spinning asbestos exposed area in eastern China
por: Jiang, Zhaoqiang, et al.
Publicado: (2020)

Prognostic value of midkine, syndecan-1, hyaluronan synthase-2, sestrin-1, laminin subunit alpha-4 and fibulin-3 for malignant pleural mesothelioma
por: Akgun, Hakan, et al.
Publicado: (2021)

The Pathophysiological Significance of Fibulin-3
por: Livingstone, Imogen, et al.
Publicado: (2020)

Fibulin-2 Facilitates Malignant Progression of Hepatocellular Carcinoma
por: Hu, Xinyan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l5o4hq7tcujfr2dj4ungmj10p6